MRI in Radiation Therapy

Peer-to-peer exchange of protocols, articles and tips

MRI in Radiation Therapy
 
Contacta Con Nosotros

From technology to clinical applications, here you find talks that allow you to continuously expand your knowledge and perfect the ability to exploit the full potential of your investment, your MAGNETOM System.


BrICS - spectroscopic MRI for dose-escalated RT

Hyunsuk Shim, Ph.D. et al., Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

Glioblastoma is the most common primary adult brain tumor in the US, with over 10,000 cases diagnosed each year. The current standard of care for these patients is the removal of as much tumor as possible via neurosurgery followed by radiation therapy and concurrent chemotherapy. Despite aggressive treatment, glioblastomas continue to progress and recur within months of treatment, and median survival remains poor at 15 months. Thus, better approaches are needed for targeting both enhancing and non-enhancing tumor to maximize the benefits of high dose radiation.

The Brain Imaging Collaboration Suite (BrICS)4 is a web-based software designed specifically to integrate spectroscopic MRI with clinical imaging, enabling physicians to evaluate metabolic activity, review underlying spectra on a voxel-basis, and delineate target volumes for RT planning. By making whole-brain spectroscopic MRI more accessible for clinical decision-making and treatment decisions through an easy-to-use, collaborative web application, we can improve patient outcomes and drive future of state-of-the-art glioblastoma care.
 

Further Reading

Spectroscopic MRI for dose-escalated radiation therapy

Hyunsuk Shim, Ph.D. et al., Department of Radiation Oncology, Winship Cancer Institute of Emory University, Atlanta, GA, USA

 


Clinical Talks

Watching Cancer Develop Multidrug Resistance

Prof. Anwar R. Padhani, MB, BS, FRCP, FRCR et al., Paul Strickland Scanner Centre, Northwood, Middlesex, United Kingdom

Tumor therapy assessment with OncoTreat

Peter Gall, Ph.D., Siemens Healthineers, Erlangen, Germany

MRI in the Radiotherapy Process, Now and in the Future

Mikael Karlsson, Umeå University Hospital, Umeå, Sweden

1The products/features shown on this webpage are not commercially available in all countries. Due to regulatory reasons their future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

2syngo.via VB10 and the syngo.via VB10 based software options are currently under development, and not for sale in the U.S., China and other countries. Due to regulatory reasons its future availability cannot be guaranteed. Please contact your local Siemens organization for further details.

3syngo.via VB10 and the syngo.via based software options are currently under development; not for sale in the U.S. and other countries. Future availability cannot be guaranteed.

4WIP, the product is currently under development and is not for sale in the US and in other countries. Its future availability cannot be ensured.

The herein illustrated statements made by Siemens’ customers and physicians are based on their own and discrete opinion and do not reflect Siemens' opinion. Siemens dissociates from the content and Siemens does not intend to promote the content of the statement as true, state of the art or as Siemens opinion. The Siemens' customers and physicians have not made these statements due to any financial support or contribution by Siemens or due to any other contractual obligation. The distribution of these statements by Siemens shall only illustrate the variety of different opinions and approaches regarding MR technology.